Dupixent (dupilumab) blocks IL-4Rα, inhibiting both IL-4 and IL-13 signaling. It is the dominant biologic in atopic dermatitis and asthma, expanding rapidly into COPD, EoE, and prurigo nodularis.
Dupixent binds to IL-4Rα, blocking both IL-4 (Type 1) and IL-13 (Type 2) signaling that drive Type 2 inflammation. Reduces cytokine production, IgE switching, eosinophil recruitment, and mucus without immunosuppression.
Annual revenue trajectory
Revenue of competing drugs in the same class
6 indications
All approved therapeutic uses
Dupixent is the dominant biologic in atopic dermatitis with >70% share and is rapidly expanding in asthma and COPD. Broadening label across Type 2 diseases creates a unique multi-indication franchise.
Projected to reach $15B+ by 2027, driven by COPD approval (massive new market), pediatric expansion, and geographic growth. COPD alone opens a $5B+ opportunity.
| Drug | Company | Revenue |
|---|---|---|
| Adbry (tralokinumab) | LEO Pharma | $0.5B |
| Nucala (mepolizumab) | GSK | $2.0B |
| Fasenra (benralizumab) | AstraZeneca | $1.5B |
| Cibinqo (abrocitinib) | Pfizer | $0.3B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.